Near-infrared (NIR) light therapy appears safe and may help reduce inflammation in hemodialysis patients, according to a new pilot study from Peking University. Researchers treated 42 kidney dialysis patients with 30 minutes of NIR irradiation and found significant decreases in inflammatory markers, opening a potential new avenue for protecting the surgical blood vessels that dialysis depends on.

What Is This Study About, and Why Should Dialysis Patients Care?

Hemodialysis patients rely on a surgically created connection between an artery and vein, called an arteriovenous fistula (AVF), to access their bloodstream during treatment. The problem is that these fistulas often fail within the first year due to inflammation and abnormal blood vessel growth. Between 20 and 27 percent of AVFs experience primary failure within 12 months of creation, forcing patients to undergo additional interventional procedures. Researchers have been searching for non-invasive ways to protect these critical access points, and this new trial suggests NIR therapy might be one answer.

The study, conducted between July and September 2023 at Peking University Third Hospital, enrolled 44 maintenance hemodialysis (MHD) patients and randomized them to receive either NIR treatment or standard care. A total of 42 participants completed the trial. The NIR device used in the study operated at wavelengths between 600 and 3,400 nanometers, with an energy density of 31.8 joules per square centimeter delivered over a single 30-minute session.

What Did the Researchers Find About Inflammation and Immune Function?

The most striking findings involved inflammatory markers. Interleukin-6 (IL-6), a key inflammatory protein, decreased significantly in the NIR group compared to controls. At the site of the fistula itself, IL-6 dropped by 0.46 picograms per milliliter in the NIR group, while it actually increased by 0.23 picograms per milliliter in the control group. Systemically, the difference was even more pronounced: IL-6 fell by 0.53 picograms per milliliter in the treated group versus a rise of 0.86 picograms per milliliter in controls.

The therapy also boosted protective immune markers. After the 30-minute treatment, interleukin-10 (IL-10), an anti-inflammatory protein, increased significantly at the fistula site in the NIR group. Additionally, the ratio of CD4+ to CD8+ immune cells, which reflects immune balance, improved in both the local fistula area and systemically in treated patients. These changes suggest that NIR therapy may help shift the immune environment away from the chronic inflammation that damages blood vessels.

How Does Near-Infrared Light Work at the Cellular Level?

Near-infrared light is part of a therapeutic approach called photobiomodulation (PBMT), which uses specific wavelengths of light to stimulate cellular repair and reduce inflammation. Unlike visible red light, NIR penetrates deeper into tissue because it is less absorbed by blood and melanin, allowing it to directly reach blood vessels, lymphatic vessels, and nerve endings. At the cellular level, NIR light enhances the availability of nitric oxide, a molecule that promotes blood vessel relaxation and improves blood flow. It also reduces the production of superoxide anions, harmful molecules that trigger inflammation and oxidative stress.

The therapy works by downregulating adhesion molecules that cause immune cells to stick to blood vessel walls, a key step in inflammation. By reducing these adhesion signals and suppressing pro-inflammatory pathways, NIR therapy may help prevent the abnormal blood vessel growth and narrowing that leads to fistula failure.

Is Near-Infrared Therapy Safe for Dialysis Patients?

Safety was a primary concern in this pilot trial. Researchers monitored skin temperature at the fistula site as the main safety indicator and found no adverse events. The study notes that photobiomodulation is generally well-tolerated, even at much higher energy doses. Red light has not been shown to cause DNA damage, even at fluences up to 1,280 joules per square centimeter, far exceeding the 31.8 joules per square centimeter used in this trial. However, this was a short-term study of a single 30-minute session, so longer-term safety data would be needed before NIR therapy becomes standard clinical practice.

How Does This Fit Into the Broader Research on Light Therapy and Sauna?

This hemodialysis study represents a distinct application of light therapy compared to the broader research on red light and infrared sauna for general health. While sauna research, particularly the landmark KIHD cohort study of 2,315 Finnish men followed for over 20 years, has documented cardiovascular and longevity benefits from heat exposure, the mechanisms differ from photobiomodulation. Sauna therapy works primarily through sustained heat exposure at specific temperature ranges, whereas photobiomodulation uses specific wavelengths of light to trigger cellular changes. The NIR hemodialysis study bridges these two areas by using light therapy to address a specific vascular problem in a medically vulnerable population.

What Are the Next Steps for This Research?

This pilot trial is intentionally small and short-term, designed to establish safety and identify promising biological signals rather than prove clinical benefit. The researchers explicitly note that this is the first clinical assessment of both the safety profile and hemodynamic impact of NIR irradiation on AVFs in a controlled trial design. Larger, longer-term randomized controlled trials would be needed to determine whether repeated NIR sessions can actually prevent fistula failure and improve patient outcomes. Such studies would also need to establish the optimal treatment frequency, duration, and timing relative to fistula creation or intervention.

Steps to Understanding Light Therapy Research in Clinical Settings

• Distinguish between study types: Pilot trials like this one establish safety and identify promising signals but do not prove that a therapy works. Larger randomized controlled trials with longer follow-up are needed before a therapy becomes standard clinical practice.
• Look for biological plausibility: The study measured specific inflammatory markers and immune cell ratios that are known to contribute to blood vessel damage, making the findings more credible than if it had only measured subjective symptoms.
• Check for safety monitoring: Reputable clinical trials include explicit safety assessments and report adverse events. This study monitored skin temperature and found no safety concerns, but longer-term data would strengthen confidence.
• Understand wavelength specificity: Different wavelengths of light penetrate tissue to different depths and trigger different cellular responses. Near-infrared light reaches deeper structures like blood vessels, whereas visible red light primarily affects surface tissues.

For dialysis patients and their care teams, this research offers a glimmer of hope for a non-invasive, drug-free approach to protecting vascular access. However, it remains preliminary. The next phase of research will determine whether NIR therapy can be translated from a single 30-minute session in a research setting into a practical, effective treatment that dialysis centers can offer routinely. Until then, this pilot study serves as proof of concept that light therapy deserves further investigation as a tool to reduce the inflammation that threatens one of the most critical lifelines for people with kidney disease.